Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical industry services provider Ergomed reported a rise in annual profit as acquisitions in the US bolstered performance.
For the full Year ended 31 December 2020, pre-tax profit more than doubled to £12.6 million from £5.0 million year-on-year as revenue rose 26.5% to £86.4 million.
A strong business development performance in 2020 resulted in sales increasing by 41.9% to £117.8 million, driven by the company's 'broader geographic footprint arising from organic expansion into the USA and Asia,' Ergomed said.
'We have started 2021 in a strong position focused on our vision to achieve global leadership in specialised pharmaceutical services addressing unmet medical needs and patient safety,' it added.
At 9:04am: (LON:ERGO) Ergomed PLC share price was 0p at 795p